Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s product pipeline includes batoclimab and IMVT-1402, both of which are fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor. Co. is developing batoclimab, its first prodcut candidate, and IMVT-1402, its second product candidate, in autoimmune diseases for which there is evidence that pathogenic IgG antibodies drive disease manifestation. Co. is developing batoclimab for myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and Graves' disease. The IMVT YTD return is shown above.
The YTD Return on the IMVT YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether IMVT YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IMVT YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|